| Literature DB >> 29188218 |
Martina Amanzio1,2, Sara Palermo1, Milena Zucca3, Rosalba Rosato1,4, Elisa Rubino3, Daniela Leotta5, Massimo Bartoli1, Innocenzo Rainero3.
Abstract
BACKGROUND: Recent studies have suggested that cognitive functions in patients with neurocognitive disorders have a significant role in the pathogenic mechanisms of frailty. Although pre-frailty is considered an intermediate, preclinical state, epidemiological research has begun to dislodge cognition and frailty into their specific subcomponents to understand the relationship among them. We aim to analyse the possible association between pre-frailty and neuropsychological variables to outline which factors can contribute to minor and major neurocognitive disorders.Entities:
Keywords: Alzheimer’s disease; comprehensive geriatric assessment; executive dysfunction; mild cognitive impairment; pre-frailty
Year: 2017 PMID: 29188218 PMCID: PMC5694746 DOI: 10.3389/fmed.2017.00199
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Demographic characteristics and frailty evaluation by a comprehensive geriatric assessment.
| Maximum scores | Mean ± SD | Cutoff | |
|---|---|---|---|
| Gender (male/female) | 22/38 | ||
| Age (years) | 66.62 ± 6.80 | ||
| Schooling (years) | 9.28 ± 3.86 | ||
| Early cognitive symptoms complaints (months) | 31.15 ± 27.82 | ||
| Clinical dementia rating scale | 0.78 ± 0.44 | ||
| Activity of daily living scale | 8 | 5.70 ± 0.53 | ≥4 |
| Instrumental activity of daily living scale | 6 | 6.63 ± 1.55 | ≥6 |
| Short portable mental state questionnaire | 10 | 2.46 ± 1.63 | ≤2 |
| Cumulative illness rating scale—comorbidity index | 13 | 1.43 ± 1.42 | |
| Mini nutritional assessment | 30 | 21.32 ± 3.62 | ≥24 |
| Exton Smith Scale | 20 | 18.80 ± 1.47 | ≥15 |
| Polypharmacy | 4.12 ± 2.46 | ||
| Social condition | Household | ||
| Multidimensional prognostic index | 1 | 0.19 ± 0.12 | |
| F1 | % = 97 | ||
| F2 | % = 3 |
Wherever there is a normative value, the cutoff scores are given in the statistical normal direction. Cells in grey indicate the absence of a normative cutoff.
.
Neuropsychological and neuropsychiatric assessment synopsis.
| Maximum scores | Mean ± SD | Cutoff | |
|---|---|---|---|
| Mini-mental state examination | 30 | 25.02 ± 2.85 | ≥24 |
| Addenbrooke’s cognitive examination—revised version | 100 | 69.57 ± 12.60 | ≥82 |
| Attentional matrices | 60 | 30.52 ± 9.91 | ≥31 |
| Trial making test A | 500 | 110.73 ± 82.92 | ≤94 |
| Trial making test B | 500 | 297.18 ± 158.12 | ≤283 |
| Trial making test B-A | 194.92 ± 127.11 | ≤187 | |
| Babcock | 16 | 6.22 ± 3.72 | ≥4.75 |
| Coloured progressive matrices-36 | 36 | 22.17 ± 7.26 | ≥18.96 |
| Token test | 36 | 30.21 ± 3.61 | ≥32.69 |
| Wisconsin card sorting test % correct answers | 52.59 ± 15.44 | ≥37.1 | |
| Wisconsin card sorting test % perseverative errors | 34.34 ± 14.95 | ≤42.7 | |
| Accuracy score | 0.03 ± 0.11 | ||
| Free choice improvement | −1.17 ± 4.98 | ||
| Global monitoring | −20.13 ± 14.29 | ||
| Monitoring resolution | 0.19 ± 0.24 | ||
| Control sensitivity | −0.04 ± 0.58 | ||
| Monetary gains | 2.37 ± 1.93 | ||
| Quality of life scale in Alzheimer’s disease—patient module | 39 | 17.90 ± 8.01 | |
| Hamilton depression rating scale | 67 | 10.95 ± 7.47 | ≤7 |
| Disinhibition scale | 96 | 9.40 ± 6.95 | ≤16.9 |
| Mania scale | 44 | 2.62 ± 3.57 | ≤15 |
| Awareness of deficit questionnaire—dementia scale for instrumental activity domain | 16 | 3.20 ± 8.22 | ≤4 |
Wherever there is a normative value, the cutoff scores are given in the statistical normal direction. Cells in grey indicate the absence of a normative cutoff.
Effect of the independent variables on the multidimensional prognostic index estimated by the univariate and multiple linear regression analyses.
| Crude estimates | Adjusted estimates | ||||||
|---|---|---|---|---|---|---|---|
| Model | Independent variables | β | SE | β | SE | ||
| 1 | Addenbrooke’s cognitive examination—revised version | −0.20 | 0.18 | 0.001 | −0.03 | 0.87 | 0.001 |
| Attentional matrices | −0.36 | 0.02 | 0.002 | −0.29 | 0.11 | 0.002 | |
| Babcock | −0.05 | 0.75 | 0.005 | 0.09 | 0.60 | 0.006 | |
| Token test | −0.12 | 0.43 | 0.005 | −0.01 | 0.95 | 0.005 | |
| Coloured progressive matrices-36 | −0.27 | 0.06 | 0.002 | −0.14 | 0.44 | 0.003 | |
| Model significance | |||||||
| 2 | Free choice improvement | 0.07 | 0.60 | 0.003 | 0.03 | 0.84 | 0.003 |
| Global monitoring | −0.07 | 0.60 | 0.001 | 0.11 | 0.42 | 0.001 | |
| Monitoring resolution | 0.33 | 0.02 | 0.075 | 0.073 | |||
| Monetary gains | −0.21 | 0.14 | 0.009 | − | 0.009 | ||
| Model significance | |||||||
| 3 | Hamilton depression rating scale | 0.49 | <0.00 | 0.002 | 0.002 | ||
| Mania scale | 0.09 | 0.52 | 0.005 | −0.25 | 0.07 | 0.005 | |
| Disinhibition scale | 0.50 | <0.00 | 0.002 | 0.003 | |||
| Quality of life scale in Alzheimer’s disease | −0.21 | 0.17 | 0.002 | −0.01 | 0.91 | 0.002 | |
| AQ-D scale for instrumental activity domain | −0.14 | 0.35 | 0.002 | − | 0.002 | ||
| Model significance | |||||||
In multivariable analyses standardised coefficients are adjusted for age, gender, and schooling. Values in bold italics showed a statistically significant association (.
AQ-D, Awareness Questionnaire in Dementia.